LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property

LaFleur Minerals reported assay results from its Swanson Gold Project, including 6.05 g/t Au over 8.00 metres at the Bartec target. The company identified new targets and extended gold mineralization at Jackson and Jolin. The results are part of a broader 25,570.5-metre drilling program. LaFleur Minerals is listed on the CSE, OTCQB, and FSE.

Original reporting
Published Oct 5, 2026, 11:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property — source image
Decision brief

The 30-second read

Med
01

Why it matters

The data provides fresh material for valuation models of the junior miner, but the impact on share price will depend on subsequent drilling and financing milestones.

02

Market read

Primary news for LaFleur Minerals; limited broader market effect.

03

What to watch

commodity price environment and financing capacity for further development

Relevance 6/10Novelty 7/10Timing: today

Background

LaFleur Minerals Inc. (CSE: LFLR) released new assay results from its Swanson Gold Project, highlighting a near‑surface high‑grade gold intersection at the Bartec target and additional mineralized zones at Jackson and Jolin.

Market effects

drilling results may boost interest in Canadian gold exploration sector

limited to investors focused on junior mining stocks in North America

minimal

Counterpoint

drill results could be overstated until follow‑up drilling confirms continuity

Key entities

  • LaFleur Minerals Inc.

    Junior gold miner reporting new drill results

Related articles

$LFLRFLow

LaFleur Minerals Inc.: LaFleur Minerals Appoints Andrew Elinesky as Chief Executive Officer and Provides Update on Beacon Gold Mill Recommissioning Work and Swanson Bulk Sample Progress

LaFleur Minerals Inc. (CSE: LFLR) appointed Andrew Elinesky as CEO, effective immediately. The company also provided updates on the Beacon Gold Mill recommissioning, which is over 95% complete, and a site visit by Trafigura for potential gold doré offtake arrangements. Elinesky brings extensive executive experience in mining and financial leadership. The company's Swanson Gold Project continues to advance with positive drilling results.

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$SHAZMed

What SharonAI (SHAZ) Said on Its Q3 Earnings Call

SharonAI (SHAZ) reported Q3 earnings, highlighting a $1.32B agreement and new contracts totaling $1.17B. The company terminated a $373M contract due to credit risk. CFO Anuj Goel noted $2.6B in capital secured since December 2025, with $1.3B in cash as of Sept. 30. The NVIDIA AICP program covers 72MW and 40,000 GPUs, with billing expected from Q3 2027. SharonAI plans to fund build-out with secured debt and expects $800M in customer deposits.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.